1. Presented By Antoni Ribas at 2014 ASCO Annual Meeting
Efficacy and Safety of the Anti-PD-1 <br />Monoclonal Antibody Pembrolizumab (MK-3475) in 411 Patients With Melanoma
Presented By Antoni Ribas at 2014 ASCO Annual Meeting

2. Presented By Antoni Ribas at 2014 ASCO Annual Meeting
Disclosures
Presented By Antoni Ribas at 2014 ASCO Annual Meeting

3. Pembrolizumab and Available Clinical Data: KEYNOTE-001 (NCT01295827)
Presented By Antoni Ribas at 2014 ASCO Annual Meeting

4. 411 Patients in Melanoma Expansion Cohorts: KEYNOTE-001
Presented By Antoni Ribas at 2014 ASCO Annual Meeting

5. KEYNOTE-001 Eligibility Criteria
Presented By Antoni Ribas at 2014 ASCO Annual Meeting

6. KEYNOTE-001 Eligibility Criteria
Presented By Antoni Ribas at 2014 ASCO Annual Meeting

7. Baseline Characteristics (1)
Presented By Antoni Ribas at 2014 ASCO Annual Meeting

8. Baseline Characteristics (2)
Presented By Antoni Ribas at 2014 ASCO Annual Meeting

9. Presented By Antoni Ribas at 2014 ASCO Annual Meeting
Summary of Exposurea and <br />Treatment-Related AEs by Prior IPI
Presented By Antoni Ribas at 2014 ASCO Annual Meeting

10. Treatment-Related AEs With Incidence >5%
Presented By Antoni Ribas at 2014 ASCO Annual Meeting

11. Presented By Antoni Ribas at 2014 ASCO Annual Meeting
Immune-Mediated AEs
Presented By Antoni Ribas at 2014 ASCO Annual Meeting

12. Presented By Antoni Ribas at 2014 ASCO Annual Meeting
Maximum Percent Change from Baseline in Tumor Sizea (Central Review, RECIST v1.1)
Presented By Antoni Ribas at 2014 ASCO Annual Meeting

13. Presented By Antoni Ribas at 2014 ASCO Annual Meeting
Maximum Percent Change from Baseline in Tumor Sizea (Central Review, irRC)
Presented By Antoni Ribas at 2014 ASCO Annual Meeting

14. Confirmed ORR in Subgroups (Central Review, RECIST v1.1)
Presented By Antoni Ribas at 2014 ASCO Annual Meeting

15. Antitumor Activity by Prior Ipilimumab and Pembrolizumab Dose/Schedule
Presented By Antoni Ribas at 2014 ASCO Annual Meeting

16. Presented By Antoni Ribas at 2014 ASCO Annual Meeting
Slide 16
Presented By Antoni Ribas at 2014 ASCO Annual Meeting

17. Presented By Antoni Ribas at 2014 ASCO Annual Meeting
Kaplan-Meier Estimate of PFS per RECIST 1.1, Independent Central Review
Presented By Antoni Ribas at 2014 ASCO Annual Meeting

18. Kaplan-Meier Estimate of Overall Survival
Presented By Antoni Ribas at 2014 ASCO Annual Meeting

19. Presented By Antoni Ribas at 2014 ASCO Annual Meeting
Summary
Presented By Antoni Ribas at 2014 ASCO Annual Meeting

20. Presented By Antoni Ribas at 2014 ASCO Annual Meeting
Acknowledgments
Presented By Antoni Ribas at 2014 ASCO Annual Meeting